Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 6/20 | 0.49 |
| ▸ | IKBKB | O14920 | 5/20 | 0.49 |
| ▸ | KIF11 | P52732 | 4/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933208 | 0.84 | KMT2A (0.40) | KIF11HSD17B1HSD17B2BRD4 | |
| SCHEMBL30240693 | 0.82 | MAOB (0.41) | CHUKIKBKBKIF11INSRMAPK8 | |
| SCHEMBL24933359 | 0.82 | HSD17B2 (0.50) | HSD17B1HSD17B2 | |
| SCHEMBL24933312 | 0.80 | BTK (0.42) | CHUKIKBKBMAPK8HSD17B1HSD17B2 | |
| SCHEMBL24933605 | 0.80 | HSD17B2 (0.41) | KIF11HSD17B1HSD17B2 | |
| SCHEMBL24933339 | 0.79 | HSD17B1 (0.41) | HSD17B1HSD17B2CHEK2 | |
| SCHEMBL24933182 | 0.79 | HSD17B1 (0.44) | HSD17B1HSD17B2CHEK2 | |
| SCHEMBL24932950 | 0.79 | HSD17B2 (0.52) | CHUKIKBKBHSD17B1HSD17B2BRD4 | |
| SCHEMBL24933053 | 0.79 | KDM4E (0.44) | HSD17B1HSD17B2PTGS2 | |
| SCHEMBL24933771 | 0.78 | IKBKB (0.42) | CHUKIKBKBKIF11HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |